Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety

Back to Search
Print
Bookmark Trial

NCT00241397

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Aarschot, , 3200, Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pain, Depression, Anxiety Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatient must be at least 18 years of age

- Consulting a General Practitioner for painful physical symptoms

- Written informed consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patient is unable to understand and comply with procedures of the study


- Patient is unable to complete the patient ratings


- Patient has an acute pain with an obvious cause

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pain, Depression, Anxiety DisorderStudy Evaluating Rhapsody Registry in Patients With Depression and Anxiety NCT00241397
  1. Aarschot,
  2. Aiseau-Presles,
  3. Anderlues,
  4. Andrimont,
  5. Angleur,
  6. Ans,
  7. Anthée,
  8. Auvelais,
  9. Avelgem,
  10. Beauraing,
  11. Beernem,
  12. Bekegem-Ichtegem,
  13. Belgrade,
  14. Bertogne,
  15. Betekom,
  16. Bierges,
  17. Binche,
  18. Bioul,
  19. Braine l'Alleud,
  20. Brugge,
  21. Brugge,
  22. Brussel,
  23. Bruxelles,
  24. Bruxelles,
  25. Bruxelles,
  26. Bruxelles,
  27. Bruxelles,
  28. Bruxelles,
  29. Bruxelles,
  30. Bruxelles,
  31. Charleroi,
  32. Ciney,
  33. Couillet,
  34. Deurne (Antwerpen),
  35. Dworp,
  36. Eghezée,
  37. Eupen,
  38. Galmaarden,
  39. Goutroux,
  40. Grimminge,
  41. Hatrival,
  42. Hemiksem,
  43. Herenthout,
  44. Hoboken,
  45. Houdeng-Aimeries,
  46. Houdeng-Goegnies,
  47. Incourt,
  48. Itegem,
  49. Jabbeke,
  50. Jambes,
  51. Jodoigne,
  52. Kapellen,
  53. Kettenis,
  54. Klemskerke,
  55. Kuurne,
  56. Laarne,
  57. Lasne,
  58. Leuven,
  59. Lobbes,
  60. Luttre,
  61. Melin,
  62. Merksem,
  63. Monceau-sur-Sambre,
  64. Morlanwelz,
  65. Moustier S/S,
  66. Noorderwijk,
  67. Oudenaarde,
  68. Ranst,
  69. Reves,
  70. Rixensart,
  71. Romsee,
  72. Rotselaar,
  73. Ruddervoorde,
  74. Sainte-Marie-sur-Semois,
  75. Schildewindeke,
  76. Schoten,
  77. St-Joris Winge,
  78. Steenokkerzeel,
  79. Waarschoot,
  80. Waha,
  81. Walem,
  82. Wavre,
  83. Wetteren,
  84. Wevelgem,
  85. Wilrijk,
  86. Wommelgem,
  87. Wondelgem,
  88. Wuustwezel-Gooreind,
  89. Zelzate,
  90. Zemst,
  91. Zetrud-Lumay,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
Official Title An Observational Study on the Presence of Depression and/or Anxiety Disorder in Patients Consulting the General Practitioner With Painful Physical Symptoms in Belgium and Luxemburg.
Brief Summary The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition
  • Pain
  • Depression
  • Anxiety Disorder
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: October 17, 2005)		2560
Original Enrollment Same as current
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Outpatient must be at least 18 years of age
  • Consulting a General Practitioner for painful physical symptoms
  • Written informed consent

Exclusion Criteria:

  • Patient is unable to understand and comply with procedures of the study
  • Patient is unable to complete the patient ratings
  • Patient has an acute pain with an obvious cause
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Belgium
Removed Location Countries  
 
Administrative Information
NCT Number NCT00241397
Other Study ID Numbers 0600B1-102003
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical Monitor, MDWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor Belgium, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date March 2007